Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL CANCER MTOR INHIBITORS INDUSTRY
2.1 Summary about Cancer mTOR Inhibitors Industry
2.2 Cancer mTOR Inhibitors Market Trends
2.2.1 Cancer mTOR Inhibitors Production & Consumption Trends
2.2.2 Cancer mTOR Inhibitors Demand Structure Trends
2.3 Cancer mTOR Inhibitors Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Afinitor/Votubia
4.2.2 Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor
4.2.3 Torisel (Temsirolimus)
4.2.4 Evertor andndash
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Breast Cancer
4.3.2 Hematological Malignancy
4.3.3 Neuroendocrine Tumors
4.3.4 Hepatocellular Carcinoma
4.3.5 Glioblastoma
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Afinitor/Votubia
5.2.2 Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor
5.2.3 Torisel (Temsirolimus)
5.2.4 Evertor andndash
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Breast Cancer
5.3.2 Hematological Malignancy
5.3.3 Neuroendocrine Tumors
5.3.4 Hepatocellular Carcinoma
5.3.5 Glioblastoma
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Afinitor/Votubia
6.2.2 Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor
6.2.3 Torisel (Temsirolimus)
6.2.4 Evertor andndash
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Breast Cancer
6.3.2 Hematological Malignancy
6.3.3 Neuroendocrine Tumors
6.3.4 Hepatocellular Carcinoma
6.3.5 Glioblastoma
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Afinitor/Votubia
7.2.2 Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor
7.2.3 Torisel (Temsirolimus)
7.2.4 Evertor andndash
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Breast Cancer
7.3.2 Hematological Malignancy
7.3.3 Neuroendocrine Tumors
7.3.4 Hepatocellular Carcinoma
7.3.5 Glioblastoma
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Afinitor/Votubia
8.2.2 Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor
8.2.3 Torisel (Temsirolimus)
8.2.4 Evertor andndash
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Breast Cancer
8.3.2 Hematological Malignancy
8.3.3 Neuroendocrine Tumors
8.3.4 Hepatocellular Carcinoma
8.3.5 Glioblastoma
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Afinitor/Votubia
9.2.2 Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor
9.2.3 Torisel (Temsirolimus)
9.2.4 Evertor andndash
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Breast Cancer
9.3.2 Hematological Malignancy
9.3.3 Neuroendocrine Tumors
9.3.4 Hepatocellular Carcinoma
9.3.5 Glioblastoma
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Abraxis BioScience
10.1.2 Adimab
10.1.3 Celgene Corporation
10.1.4 Celator Pharmaceuticals
10.1.5 Eli Lilly
10.1.6 Exelixis
10.1.7 GlaxoSmithKline
10.1.8 HEC Pharm
10.1.9 Intellikine
10.1.10 Novartis
10.1.11 Oneness Biotech
10.1.12 PIQUR Therapeutics
10.1.13 Semafore Pharmaceuticals
10.1.14 Takeda
10.1.15 Wyeth
10.2 Cancer mTOR Inhibitors Sales Date of Major Players (2017-2020e)
10.2.1 Abraxis BioScience
10.2.2 Adimab
10.2.3 Celgene Corporation
10.2.4 Celator Pharmaceuticals
10.2.5 Eli Lilly
10.2.6 Exelixis
10.2.7 GlaxoSmithKline
10.2.8 HEC Pharm
10.2.9 Intellikine
10.2.10 Novartis
10.2.11 Oneness Biotech
10.2.12 PIQUR Therapeutics
10.2.13 Semafore Pharmaceuticals
10.2.14 Takeda
10.2.15 Wyeth
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
